INT129971

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 9
Disease Relevance 3.96
Pain Relevance 0.97

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (PVR) extracellular region (PVR) nucleolus (PVR)
plasma membrane (PVR) nucleus (PVR) cytoplasm (PVR)
Anatomy Link Frequency
bladder 1
heart 1
PVR (Homo sapiens)
Pain Link Frequency Relevance Heat
Opioid 3 99.50 Very High Very High Very High
cva 31 93.00 High High
ketamine 2 92.00 High High
Central nervous system 1 90.72 High High
Morphine 2 86.28 High High
withdrawal 5 84.96 Quite High
tolerance 5 83.72 Quite High
analgesia 2 75.00 Quite High
addiction 5 71.92 Quite High
Gabapentin 5 66.44 Quite High
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 461 99.48 Very High Very High Very High
Overactive Bladder 70 98.64 Very High Very High Very High
Coronary Heart Disease 7 98.24 Very High Very High Very High
Critical Illness 32 97.00 Very High Very High Very High
Thrombosis 8 93.32 High High
Hypotension 50 88.44 High High
Cv General 4 Under Development 39 87.08 High High
Substance Withdrawal Syndrome 1 85.32 High High
Fatigue 2 82.20 Quite High
Dyspnea 3 81.88 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the critically ill infant at risk following surgery for congenital heart disease, clinical experience supports the use of the synthetic opioids, given their ability to modulate PVR and prevent pulmonary hypertensive crisis.
Regulation (modulate) of PVR in heart associated with pulmonary hypertension, critical illness, coronary heart disease and opioid
1) Confidence 0.60 Published 2005 Journal Pediatr Ann Section Abstract Doc Link 16149752 Disease Relevance 0.65 Pain Relevance 0.82
The choice of vasopressor and inotropes in patients with acute pulmonary hypertension should take into consideration their effects on PVR and cardiac output when used alone or in combinations with other agents, and must be individualized based on individual patient response.
Regulation (effects) of PVR associated with pulmonary hypertension
2) Confidence 0.41 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605326 Disease Relevance 0.96 Pain Relevance 0
The choice of vasopressor and inotropes in patients with acute pulmonary hypertension should take in consideration their effects on PVR and cardiac output when used alone or in combinations with other agents, and must be individualized based on individual patient response.
Regulation (effects) of PVR associated with pulmonary hypertension
3) Confidence 0.41 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605326 Disease Relevance 1.09 Pain Relevance 0
The longitudinal profile of PVR did not show any relevant pattern, even in subjects who reached PVR >100 mL at some point during treatment.
Regulation (reached) of PVR
4) Confidence 0.36 Published 2010 Journal BMC Urol Section Body Doc Link PMC2939595 Disease Relevance 0.28 Pain Relevance 0
When alternative models for the dose effect on PVR were tested, the model with the minimum Akaike information criterion was the square root model, but this model was only marginally better than the linear model with similar parameter estimates.
Regulation (effect) of PVR
5) Confidence 0.22 Published 2010 Journal BMC Urol Section Body Doc Link PMC2939595 Disease Relevance 0 Pain Relevance 0
Given the considerable variability in subject data from the clinical trials with regard to PVR, logistic regression equations were developed to model the probability that PVR would exceed 100 mL in a patient treated with fesoterodine at any time point, rather than modeling changes in PVR over time using longitudinal data.
Regulation (changes) of PVR
6) Confidence 0.22 Published 2010 Journal BMC Urol Section Body Doc Link PMC2939595 Disease Relevance 0.33 Pain Relevance 0
We describe here the use of modeling and simulation to define dose-response relationships for the clinical effects of fesoterodine on key bladder diary endpoints and postvoid residual (PVR) urinary volume in patients with OAB.


Regulation (effects) of PVR in bladder associated with overactive bladder
7) Confidence 0.22 Published 2010 Journal BMC Urol Section Body Doc Link PMC2939595 Disease Relevance 0.10 Pain Relevance 0.07
In the PVR model, baseline PVR level, followed by drug dose, was the most important covariate for the probability that a patient treated for 12 weeks would develop PVR >100 mL.
Regulation (followed) of PVR
8) Confidence 0.22 Published 2010 Journal BMC Urol Section Body Doc Link PMC2939595 Disease Relevance 0 Pain Relevance 0.04
With combined iloprost and sildenafil therapy, the effect on mPAP, PVR, and CI was more pronounced and longer lasting, and the vasodilatory response was greater than for the sum of the individual therapies, suggesting treatment synergy (Ghofrani et al 2002).
Regulation (effect) of PVR
9) Confidence 0.16 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 0.55 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox